Concept validation of potential cure therapy for type 1 diabetes

T1D is a kind of autoimmune diseaseThe β cells in the islets of Langerhans of the patients are damaged, unable to provide enough insulin to maintain the normal level of blood sugar, which leads to hyperglycemia, which results in excessive drinking, urination, eating, weight loss, blurred vision, etc., even life-threateningIn the past, the main treatment of T1D was injection of exogenous insulin, but even through insulin treatment, patients still have the risk of long-term complications, such as macular edema and retinopathy (which can lead to blindness), renal failure, neurological and vascular diseases< br / > the principle of regenerative therapy developed by semma is to produce a large number of SC islets from human pluripotent stem cellsIn 2014, Professor Doug Melton's laboratory at Harvard University developed the breakthrough stem cell differentiation technology and authorized it to semma for cell therapySC islets is functionally equivalent to natural islets of LangerhansIt is used to sense the glucose level in human body and release insulin accurately, with good repeatability and stability< br / > ▲ the mechanism of SC islets cell therapy (photo source: semma company website) < br / > in the preclinical study, SC islets were delivered to non-human primates under immunosuppression, and could exist stably in their liver for more than six weeks, with insulin demand reduced by more than 60%In another study, SC islets were encapsulated in a new immune protection device developed by semma company and delivered to pigs without immunosuppressionThe device can provide immune protection, maximize the survival of SC islets and reduce rejectionSemma plans to conduct two clinical trials starting in the first half of 2020, targeting patients with diabetes and hypoglycemia who are difficult to treat< br / >, "This innovative treatment brings hope to millions of people around the world who have type 1 diabetes." < br / > reference < br / > [1] semitherapeutics announcements pre clinical proof of concept in two lead programs in type 1 diabetesRetrieved July 2, 2019, from < br / > [2] about semitherapeuticsRetrieved July 2, 2019, from < br / > original title: concept validation of potential cure therapy for type 1 diabetes mellitus, islets generated by stem cells